Capitalising on UK’s goal to become a world-leading clinical trial destination
Representatives of industry and regulation will meet in June to discuss paths forward for the UK’s clinical trials sector following…
Featured
-
-
Can pharma tariffs “Make America Manufacture Again”?
As President Trump continues to signal import tariffs on pharmaceuticals to bolster US manufacturing, experts warn this could hike costs…
-
Pharma’s AI prospects get nudged into the future with EU’s AI act
The EU Artificial Intelligence (AI) Act may protect citizens, but some experts in the life sciences industry are worried about…
-
Investors insist halted biotech IPOs will return in 2025
Investors remain optimistic for a return of biotech IPOs in 2025 despite a market downturn following the announcement of US…
-
Myostatin inhibitors target muscle loss prevention to fill gap in GLP-1RA market
As weight loss drugs boom in popularity, some companies are focusing their sights on therapies for muscle loss prevention, a…
-
Small biotechs shoulder the burdens of an uncertain biopharma sector
Recent US tariffs and federal funding cuts mean a heightened uncertainty for biopharma investors, and small biotechs are set to…
-
Caribou cuts pipeline and workforce to focus on lead CAR-T programmes
Caribou Biosciences is narrowing its pipeline and reducing its workforce by approximately 32% amid continued challenges in the cell and…
-
Trump order eases Medicare price negotiation for small molecule drugs
US President Donald Trump has issued a broad executive order to lower prescription drug prices in the country, notably including…
-
Can AI replace medical writers? Experts say not immediately
Artificial intelligence (AI) is said to be exponentially faster and effective at writing lengthy and complex clinical trial documents, but…
-
Streeting promises UK pharma quick action on VPAG frustration
The UK pharma industry can expect resolutions on a range of issues, including VPAG [Voluntary Scheme for Branded Medicines Pricing…
